Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur

Francesca Barbisan, Alfredo Santinelli, Roberta Mazzucchelli, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Theodorus Van Der Kwast, Rodolfo Montironi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND. Papillary urothelial neoplasm of low malignant potential (PUNLMP) is a clinically significant lesion because recurrence occurs in approximately 35% of patients. To date, it is not possible to identify those cases that will recur based on conventional histopathologic assessment. The objective of the current study was to evaluate immunohistochemically tissue expression of fibroblast growth factor receptor 3 (FGFR3), cytokeratin 20 (CK20), and MIB-1 in nonrecurrent and recurrent PUNLMP. METHODS. FGFR3, CK20, and MIB-1 were investigated by immunohistochemistry (IHC) in 80 PUNLMP cases (41 nonrecurrent and 39 recurrent), in 4 cases of normal urothelium (NU), and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). Statistics included discriminant analysis. RESULTS. NU demonstrated a weak to moderate FRFG3 staining intensity, a superficial pattern of CK20 staining, and low proliferative activity. UC was found to have FGFR3 staining similar to NU, an abnormal CK20 expression, and high proliferative activity. The nonrecurrent PUNLMP group demonstrated strong FGFR3 intensity in 80.5% of the cases (vs 56.4% of the recurrent cases), a superficial CK20 staining pattern in 53.7% of the cases (vs 28.2% of the recurrent cases), and a percentage of MIB-1-positive nuclei below the median value of all the PUNLMP cases in 61% of the cases (35.9% in the recurrent cases). The differences were statistically significant. Discriminant analysis based on these 3 features demonstrated that 67.5% of cross-validated grouped PUNLMP cases were correctly allocated, with 73.2% of the nonrecurrent and 61.5% of the nonrecurrent cases being correctly classified. The specificity and sensitivity were 73.1% and 61.5%, respectively. CONCLUSIONS. Strong immunohistochemical expression of FGFR3, a superficial staining pattern of CK20, and a low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.

Original languageEnglish
Pages (from-to)636-644
Number of pages9
JournalCancer
Volume112
Issue number3
DOIs
StatePublished - Feb 1 2008

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Keratin-20
Staining and Labeling
Urothelium
Neoplasms
Discriminant Analysis
Carcinoma
Immunohistochemistry
Recurrence
Sensitivity and Specificity
Muscles

Keywords

  • Cytokeratin 20 (CK20)
  • Fibroblast growth factor receptor 3 (FGFR3)
  • MIB-1
  • Papillary urothelial neoplasm of low malignant potential
  • Recurrence
  • Urothelium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. / Barbisan, Francesca; Santinelli, Alfredo; Mazzucchelli, Roberta; Lopez-Beltran, Antonio; Cheng, Liang; Scarpelli, Marina; Van Der Kwast, Theodorus; Montironi, Rodolfo.

In: Cancer, Vol. 112, No. 3, 01.02.2008, p. 636-644.

Research output: Contribution to journalArticle

Barbisan, Francesca ; Santinelli, Alfredo ; Mazzucchelli, Roberta ; Lopez-Beltran, Antonio ; Cheng, Liang ; Scarpelli, Marina ; Van Der Kwast, Theodorus ; Montironi, Rodolfo. / Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. In: Cancer. 2008 ; Vol. 112, No. 3. pp. 636-644.
@article{72f345e426d344469e1de26a973b45c1,
title = "Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur",
abstract = "BACKGROUND. Papillary urothelial neoplasm of low malignant potential (PUNLMP) is a clinically significant lesion because recurrence occurs in approximately 35{\%} of patients. To date, it is not possible to identify those cases that will recur based on conventional histopathologic assessment. The objective of the current study was to evaluate immunohistochemically tissue expression of fibroblast growth factor receptor 3 (FGFR3), cytokeratin 20 (CK20), and MIB-1 in nonrecurrent and recurrent PUNLMP. METHODS. FGFR3, CK20, and MIB-1 were investigated by immunohistochemistry (IHC) in 80 PUNLMP cases (41 nonrecurrent and 39 recurrent), in 4 cases of normal urothelium (NU), and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). Statistics included discriminant analysis. RESULTS. NU demonstrated a weak to moderate FRFG3 staining intensity, a superficial pattern of CK20 staining, and low proliferative activity. UC was found to have FGFR3 staining similar to NU, an abnormal CK20 expression, and high proliferative activity. The nonrecurrent PUNLMP group demonstrated strong FGFR3 intensity in 80.5{\%} of the cases (vs 56.4{\%} of the recurrent cases), a superficial CK20 staining pattern in 53.7{\%} of the cases (vs 28.2{\%} of the recurrent cases), and a percentage of MIB-1-positive nuclei below the median value of all the PUNLMP cases in 61{\%} of the cases (35.9{\%} in the recurrent cases). The differences were statistically significant. Discriminant analysis based on these 3 features demonstrated that 67.5{\%} of cross-validated grouped PUNLMP cases were correctly allocated, with 73.2{\%} of the nonrecurrent and 61.5{\%} of the nonrecurrent cases being correctly classified. The specificity and sensitivity were 73.1{\%} and 61.5{\%}, respectively. CONCLUSIONS. Strong immunohistochemical expression of FGFR3, a superficial staining pattern of CK20, and a low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.",
keywords = "Cytokeratin 20 (CK20), Fibroblast growth factor receptor 3 (FGFR3), MIB-1, Papillary urothelial neoplasm of low malignant potential, Recurrence, Urothelium",
author = "Francesca Barbisan and Alfredo Santinelli and Roberta Mazzucchelli and Antonio Lopez-Beltran and Liang Cheng and Marina Scarpelli and {Van Der Kwast}, Theodorus and Rodolfo Montironi",
year = "2008",
month = "2",
day = "1",
doi = "10.1002/cncr.23212",
language = "English",
volume = "112",
pages = "636--644",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur

AU - Barbisan, Francesca

AU - Santinelli, Alfredo

AU - Mazzucchelli, Roberta

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Scarpelli, Marina

AU - Van Der Kwast, Theodorus

AU - Montironi, Rodolfo

PY - 2008/2/1

Y1 - 2008/2/1

N2 - BACKGROUND. Papillary urothelial neoplasm of low malignant potential (PUNLMP) is a clinically significant lesion because recurrence occurs in approximately 35% of patients. To date, it is not possible to identify those cases that will recur based on conventional histopathologic assessment. The objective of the current study was to evaluate immunohistochemically tissue expression of fibroblast growth factor receptor 3 (FGFR3), cytokeratin 20 (CK20), and MIB-1 in nonrecurrent and recurrent PUNLMP. METHODS. FGFR3, CK20, and MIB-1 were investigated by immunohistochemistry (IHC) in 80 PUNLMP cases (41 nonrecurrent and 39 recurrent), in 4 cases of normal urothelium (NU), and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). Statistics included discriminant analysis. RESULTS. NU demonstrated a weak to moderate FRFG3 staining intensity, a superficial pattern of CK20 staining, and low proliferative activity. UC was found to have FGFR3 staining similar to NU, an abnormal CK20 expression, and high proliferative activity. The nonrecurrent PUNLMP group demonstrated strong FGFR3 intensity in 80.5% of the cases (vs 56.4% of the recurrent cases), a superficial CK20 staining pattern in 53.7% of the cases (vs 28.2% of the recurrent cases), and a percentage of MIB-1-positive nuclei below the median value of all the PUNLMP cases in 61% of the cases (35.9% in the recurrent cases). The differences were statistically significant. Discriminant analysis based on these 3 features demonstrated that 67.5% of cross-validated grouped PUNLMP cases were correctly allocated, with 73.2% of the nonrecurrent and 61.5% of the nonrecurrent cases being correctly classified. The specificity and sensitivity were 73.1% and 61.5%, respectively. CONCLUSIONS. Strong immunohistochemical expression of FGFR3, a superficial staining pattern of CK20, and a low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.

AB - BACKGROUND. Papillary urothelial neoplasm of low malignant potential (PUNLMP) is a clinically significant lesion because recurrence occurs in approximately 35% of patients. To date, it is not possible to identify those cases that will recur based on conventional histopathologic assessment. The objective of the current study was to evaluate immunohistochemically tissue expression of fibroblast growth factor receptor 3 (FGFR3), cytokeratin 20 (CK20), and MIB-1 in nonrecurrent and recurrent PUNLMP. METHODS. FGFR3, CK20, and MIB-1 were investigated by immunohistochemistry (IHC) in 80 PUNLMP cases (41 nonrecurrent and 39 recurrent), in 4 cases of normal urothelium (NU), and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). Statistics included discriminant analysis. RESULTS. NU demonstrated a weak to moderate FRFG3 staining intensity, a superficial pattern of CK20 staining, and low proliferative activity. UC was found to have FGFR3 staining similar to NU, an abnormal CK20 expression, and high proliferative activity. The nonrecurrent PUNLMP group demonstrated strong FGFR3 intensity in 80.5% of the cases (vs 56.4% of the recurrent cases), a superficial CK20 staining pattern in 53.7% of the cases (vs 28.2% of the recurrent cases), and a percentage of MIB-1-positive nuclei below the median value of all the PUNLMP cases in 61% of the cases (35.9% in the recurrent cases). The differences were statistically significant. Discriminant analysis based on these 3 features demonstrated that 67.5% of cross-validated grouped PUNLMP cases were correctly allocated, with 73.2% of the nonrecurrent and 61.5% of the nonrecurrent cases being correctly classified. The specificity and sensitivity were 73.1% and 61.5%, respectively. CONCLUSIONS. Strong immunohistochemical expression of FGFR3, a superficial staining pattern of CK20, and a low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.

KW - Cytokeratin 20 (CK20)

KW - Fibroblast growth factor receptor 3 (FGFR3)

KW - MIB-1

KW - Papillary urothelial neoplasm of low malignant potential

KW - Recurrence

KW - Urothelium

UR - http://www.scopus.com/inward/record.url?scp=38749108486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749108486&partnerID=8YFLogxK

U2 - 10.1002/cncr.23212

DO - 10.1002/cncr.23212

M3 - Article

VL - 112

SP - 636

EP - 644

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -